Aldeyra Therapeutics, Inc. April 4, 2025 Please complete the form below to contact Kaplan Fox regarding the Aldeyra Therapeutics, Inc. Investigation: Join a Case First Name * Last Name * Email Address * Phone Number * Ticker Symbol Or Company Name * Please Insert Your Estimation Of Losses In USD * Are you a current or former employee of the company mentioned having traded above? * Yes No Captcha Submit If you are human, leave this field blank. Principle Contacts Jeffrey P. Campisi JCampisi@kaplanfox.comLaurence D. KingLKing@kaplanfox.com Kaplan Fox & Kilsheimer LLP is Investigating Aldeyra Therapeutics, Inc. (ALDX) for Potential Securities Law Violations Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Aldeyra Therapeutics, Inc. (“Aldeyra Therapeutics” or the “Company”) (NASDAQ: ADLX). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are an Aldeyra Therapeutics investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing jcampisi@kaplanfox.com or by calling (212) 329-8571. On April 3, 2025, before the market opened, Aldeyra Therapeutics disclosed that the FDA issued a second Complete Response Letter (“CRL”) for reproxalap, its lead dry eye disease drug candidate. According to the Company, the CRL stated that the NDA “failed to demonstrate efficacy in adequate and well controlled studies in treating ocular symptoms associated with dry eyes” and that the Company should conduct “at least one additional adequate and well-controlled study to demonstrate a positive effect on the treatment for ocular symptoms of a dry eye.” The Company further stated that the CRL “identified concerns with the data from the trial submitted to the NDA that may have affected interpretation of the results, which the FDA stated may be related to methodological issues, including a difference in baseline scores across treatments arms.” Todd C. Brady, the President and Chief Executive Officer of the Company stated that “[p]ending positive results from the ongoing clinical trials and discussions with the FDA, we look forward to a potential NDA resubmission mid-year 2025.” Following this news, the price of Aldeyra Therapeutics stock fell $3.91 per share, or over 73%, to close at $1.42 per share on heavier than average trading volume. WHY CONTACT KAPLAN FOX Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this investigation, please contact: CONTACT: Jeffrey P. CampisiKAPLAN FOX & KILSHEIMER LLP800 Third Avenue, 38th FloorNew York, New York 10022(212) 329-8571jcampisi@kaplanfox.com Laurence D. KingKAPLAN FOX & KILSHEIMER LLP1999 Harrison Street, Suite 1560Oakland, California 94612(415) 772-4704lking@kaplanfox.com The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client. Any information you submit will be maintained as confidential. If Kaplan Fox, in its sole discretion, believes that you might be an appropriate client, Kaplan Fox will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases. Connect with Kaplan Fox. Receive a complimentary case review now. Contact Us ICU Medical, Inc. See the Case Ibotta, Inc. See the Case Aldeyra Therapeutics, Inc. See the Case Franklin Resources, Inc. See the Case Open Lending Corporation See the Case The Bancorp, Inc. See the Case The Vita Coco Company, Inc. See the Case BigBear.ai Holdings See the Case Viatris Inc. See the Case Zynex Inc. See the Case Hesai Group See the Case Ready Capital Corporation See the Case
